Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feedernovartis.com
English RSS Feed
Get the latest updates from English RSS Feed directly as they happen.
Follow now 131 followers
Latest posts
Last updated 1 day ago
Novartis receives positive CHMP opinion for Itvisma® for spinal muscular atrophy (SMA)
1 day ago
Novartis receives positive CHMP opinion for Itvisma® for spinal muscular atrophy (SMA)...
Novartis malaria treatment Coartem® Baby receives WHO prequalification, paving way for greater access for newborns and young infants
1 day ago
Novartis malaria treatment Coartem® Baby receives WHO prequalification, paving way for greater...
New long term social impact and sustainability targets
15 days ago
New long term social impact and sustainability targets metzgma4 Fri, 04/10/2026 -...
Novartis announces expansion of community health programs to close gaps in heart disease and cancer care, targeting more than 30 countries by 2030
17 days ago
Novartis announces expansion of community health programs to close gaps in heart...
Working with communities to close gaps in heart disease and cancer care
25 days ago
Working with communities to close gaps in heart disease and cancer care...
Managing Quality of Life with CML
26 days ago
Managing Quality of Life with CML halesmi2 Mon, 03/30/2026 - 11:12 Read...
Novartis IgAN data in New England Journal of Medicine show Fabhalta® slowed kidney function decline by 49.3%
28 days ago
Novartis IgAN data in New England Journal of Medicine show Fabhalta® slowed...
Novartis withdraws EMA application for adding new indication for Pluvicto®
29 days ago
Novartis withdraws EMA application for adding new indication for Pluvicto® weberfr8 Fri...
Novartis agrees to acquire Excellergy, Inc., building on allergy leadership with next-generation anti-IgE innovation
30 days ago
Novartis agrees to acquire Excellergy, Inc., building on allergy leadership with next-generation...
Novartis presents new data on early symptom relief and long-term control in complex skin diseases at AAD 2026
about 1 month ago
Novartis presents new data on early symptom relief and long-term control in...
Novartis agrees to acquire a pan-mutant-selective PI3Kα inhibitor, strengthening its breast cancer pipeline
about 1 month ago
Novartis agrees to acquire a pan-mutant-selective PI3Kα inhibitor, strengthening its breast cancer...
Building the Future: Novartis Innovation Lab - AI, Game Studio, XR & Emerging Tech
about 1 month ago
Building the Future: Novartis Innovation Lab - AI, Game Studio, XR &amp...